In recent years, AFP’s potential diagnostic and prognostic utility in gastric cancer has garnered increasing attention, particularly within subtypes such as gastric hepatoid adenocarcinoma (GHA), where elevated levels are significantly correlated with tumor development, progression, and prognosis. This evidence concerns the gene AFP and gastric cancer.